Leeds-based medical technology company Microneedle Solutions has closed an oversubscribed financing round to progress its Miracus needle-free drug delivery platform into first-in-human clinical trials with the NHS this year.
The Leeds investment round attracted participation from notable institutional and angel investors including Pioneer Group, SFC Capital, Cambridge Angels, Southern Angel Investor Club and Sheffield Angels, alongside strong follow-on support from existing shareholders.
Microneedle Solution is developing patch-based technology that enables painless, self-administered medicine delivery without needles, cold chain storage requirements or the costs associated with traditional needle-based administration.
Henry Dunne, CEO of MNS, said:
“This funding is a real testament to the hard work the team has put in over the last couple of years building and validating the Miracus platform, a pain-free patch delivery system that costs less than traditional needles and eliminates the need for cold chain storage. I am pleased at the breadth and depth of investors joining us in our mission to provide patients, clinicians and industry with better options for drug delivery that improve global access to medicines. This funding will support the preparation and delivery of our key first-in-human trial this year.”
Dr Glenn Crocker, MBE, Executive Director of Pioneer Group:
“It has been so satisfying to see the MNS team come through the Pioneer Accelerator programme and develop the business to this stage in just two years. The progress made is a huge credit to the hard work and dedication of the founders. We were delighted to follow our initial pre-seed investment with funding in this round and look forward to seeing this exciting technology brought to market soon.”
The financing milestone moves MNS closer to clinical validation and commercialisation of technology that aims to transform healthcare accessibility by replacing needle-and-syringe delivery systems largely unchanged for over two centuries.
Why this matters for Leeds
MNS’s oversubscribed funding demonstrates Leeds’ strength in attracting investment and developing breakthrough medical technology, reinforcing the city’s reputation as a healthtech innovation hub. MNS exemplifies the city’s ability to nurture companies solving global healthcare challenges while creating high-value jobs in life sciences, strengthening Leeds’ position competing for healthtech investment and talent nationally.
